Primary hyperoxaluria is a rare inherited disorder that results from a deficiency of D-glycerate dehydrogenase activity in the liver. The elevated urinary oxalate excretion that occurs in this disease can result in kidney failure and premature death due to the tissue deposition of calcium oxalate crystals. Our long-term objectives are to identify the genetic changes that cause the disease, develop techniques for its rapid and accurate diagnosis, to understand the physiological role of D-glycerate dehydrogenase, and to design therapies to treat the disease.
The specific aims of this proposal are to (1) determine the nucleotide sequence, structure, and chromosomal location of the gene coding for D-glycerate dehydrogenase, (2) identify mutations in the gene of individuals with primary hyperoxaluria type 2 and develop PCR methods to detect these mutations, (3) produce and purify a recombinant form of the enzyme, (4) determine the tissue expression and intracellular localization of DGDH, and (5) examine the properties of the recombinant DGDH. To make this research possible the cDNA for the human D-glycerate dehydrogenase gene has been sequenced and shown to encode for the enzyme by transfection assays in COS cells. Molecular biology techniques will be utilized to obtain the complete sequence of the gene, to identify the changes that occur in the genes of individuals with the disease, and to obtain recombinant protein. The chromosomal location of the gene will be determined using fluorescent in situ hybridization techniques. The proposed research should greatly enhance our understanding of the cause of the disease, will assist in the development of treatments and diagnoses for the disease, and will facilitate our understanding of the physiological functions of the enzyme.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK054468-02
Application #
6177695
Study Section
Special Emphasis Panel (ZRG1-UROL (01))
Program Officer
Nyberg, Leroy M
Project Start
1999-05-01
Project End
2002-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
2
Fiscal Year
2000
Total Cost
$208,451
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Surgery
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Patel, Mikita; Yarlagadda, Vidhush; Adedoyin, Oreoluwa et al. (2018) Oxalate induces mitochondrial dysfunction and disrupts redox homeostasis in a human monocyte derived cell line. Redox Biol 15:207-215
Fargue, Sonia; Milliner, Dawn S; Knight, John et al. (2018) Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria. J Am Soc Nephrol 29:1615-1623
Liebow, Abigail; Li, Xingsheng; Racie, Timothy et al. (2017) An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. J Am Soc Nephrol 28:494-503
Wood, Kyle D; Holmes, Ross P; Knight, John (2016) RNA interference in the treatment of renal stone disease: Current status and future potentials. Int J Surg 36:713-716
Chacko, Balu K; Zhi, Degui; Darley-Usmar, Victor M et al. (2016) The Bioenergetic Health Index is a sensitive measure of oxidative stress in human monocytes. Redox Biol 8:43-50
Williams, Jennifer; Holmes, Ross P; Assimos, Dean G et al. (2016) Monocyte Mitochondrial Function in Calcium Oxalate Stone Formers. Urology 93:224.e1-6
Fargue, Sonia; Knight, John; Holmes, Ross P et al. (2016) Effects of alanine:glyoxylate aminotransferase variants and pyridoxine sensitivity on oxalate metabolism in a cell-based cytotoxicity assay. Biochim Biophys Acta 1862:1055-62
Li, Xingsheng; Knight, John; Fargue, Sonia et al. (2016) Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase. Biochim Biophys Acta 1862:233-9
Fu, Y; Rope, R; Fargue, S et al. (2015) A mutation creating an out-of-frame alternative translation initiation site in the GRHPR 5'UTR causing primary hyperoxaluria type II. Clin Genet 88:494-8
Li, Xingsheng; Knight, John; Todd Lowther, W et al. (2015) Hydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3. Biochim Biophys Acta 1852:2700-5

Showing the most recent 10 out of 23 publications